IVIg was able to significantly ameliorate thrombocytopenia in both mouse strains, with no significant difference in platelet numbers in Myd88 deficient mice or control mice, suggesting that these therapeutics do not require Myd88 expression for its amelioration of murine passive ITP. Here, MYD88 is linked to Thrombocytopenia.